Oral Administration of Synthetic Retinoid Am80 (Tamibarotene) Decreases Brain .BETA.-Amyloid Peptides in APP23 Mice
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The purpose of this study is to investigate whether a synthetic retinoid Am80 (tamibarotene) exhibits any improving effects on amyloid precursor protein (APP)23 mice, a model of Alzheimer's disease. Am80 was orally administered in feed to 20-week (5-month)-old APP23 mice at a dose of 0 (control) or 0.5 mg/kg/d for 14 weeks. The Am80 treatment reduced significantly the insoluble Abeta levels in brain, in particular Abeta(42), while it gave no apparent effects on the soluble Abeta levels. The results suggest that oral administration of Am80 may have potency to reduce the extracellular Abeta(42) of insoluble and possibly oligomeric or protofibril forms, which are related to the cause and/or progression of Alzheimer's disease. The Am80 treatment showed no significant effect on spatial learning and memory of APP23 mice by Morris water maze analysis. The main reason for the absence of significance seems based on the large deviation and some mice both in the treated and the non-treated groups would neither swim nor make efforts to reach the platform.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Self-citationMicroglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329
El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915
Adult mouse astrocytes degrade amyloid-β in vitro and in situ
Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., Silverstein, S. C., & Husemann, J. (2003) · Nature Medicine · doi:10.1038/nm838 · Cited by 909
Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides
Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., Higgs, R., Liu, F., Malkani, S., Bales, K. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1058 · Cited by 571
IL-4-Induced Selective Clearance of Oligomeric β-Amyloid Peptide1–42 by Rat Primary Type 2 Microglia
Shimizu, E., Kawahara, K., Kajizono, M., Sawada, M., & Nakayama, H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6503 · Cited by 143
Self-citationGenomic structure and functional characterization of the human ADAM10 promoter
Prinzen, C., Müller, U., Endres, K., Fahrenholz, F., & Postina, R. (2005) · The FASEB Journal · doi:10.1096/fj.04-3619fje · Cited by 131
Towards Retinoid Therapy for Alzheimers Disease
Shudo, K., Fukasawa, H., Nakagomi, M., & Yamagata, N. (2009) · Current Alzheimer Research · doi:10.2174/156720509788486581 · Cited by 91
Self-citation
Cited by
Drug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 301
Retinoic acid signaling pathways in development and diseases
Das, B. C., Thapa, P., Karki, R., Das, S., Mahapatra, S., Liu, T.-C., Torregroza, I., Wallace, D. P., Kambhampati, S., Van Veldhuizen, P., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.11.025 · Cited by 276
Kawahara, K., Suenobu, M., Yoshida, A., Koga, K., Hyodo, A., Ohtsuka, H., Kuniyasu, A., Tamamaki, N., Sugimoto, Y., & Nakayama, H. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.01.049 · Cited by 113
“…of the ynthetic retinoid Am80, which increased IL-4 production n the T-cell system (Iwata et al., 2003), reduced brain 42 peptides in APP23 mice (Kawahara et al., 2009). ther compounds such as morphine (Roy et al., 2001), etrahydrocannabinol (Newton et al., 2009), 1 ,25-dihydroxyvitamin D3…”
Self-citationTamibarotene: A Candidate Retinoid Drug for Alzheimer’s Disease
Fukasawa, H., Nakagomi, M., Yamagata, N., Katsuki, H., Kawahara, K., Kitaoka, K., Miki, T., & Shudo, K. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00314 · Cited by 91
Self-citationReinhardt, S., Stoye, N., Luderer, M., Kiefer, F., Schmitt, U., Lieb, K., & Endres, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-19577-7 · Cited by 58
Metadata
- Authors
- Kawahara, K., Nishi, K., Suenobu, M., Ohtsuka, H., Maeda, A., Nagatomo, K., Kuniyasu, A., Staufenbiel, M., Nakagomi, M., Shudo, K., & Nakayama, H.
- Venue
- Biological and Pharmaceutical Bulletin
- Publisher
- Pharmaceutical Society of Japan
- Published
- 2009
- Volume
- 32
- Issue
- 7
- Pages
- 1307-1309
- ISSN
- 0918-6158 (ISSN-L)
- 1347-5215
- OpenAlex
- W1998314202
- Cited by
- 38
- References
- 8
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.